Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Multicenter Cohort Study) III

CompletedOBSERVATIONAL
Enrollment

2,000

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

August 30, 2021

Study Completion Date

August 30, 2021

Conditions
Aortic Dissection
Interventions
BIOLOGICAL

inflammatory response

laboratory data (leukocyte, neutrophils, monocyte, lymphocytes, platelet, fibrinogen, D-dimer, neutrophils-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio)

Trial Locations (1)

210029

The first affiliated hospital of nanjing medical university, Nanjing

Sponsors
All Listed Sponsors
collaborator

The First Affiliated Hospital with Nanjing Medical University

OTHER

collaborator

Beijing Anzhen Hospital

OTHER

collaborator

The Affiliated Hospital of Qingdao University

OTHER

collaborator

First Affiliated Hospital of Shantou University Medical College

OTHER

collaborator

The First Affiliated Hospital of Guangzhou Medical University

OTHER

collaborator

TEDA International Cardiovascular Hospital

OTHER

collaborator

Xiamen Cardiovascular Hospital

UNKNOWN

collaborator

Shanghai East Hospital Tongji University

UNKNOWN

collaborator

Tianjin Chest Hospital, Tianjin Medical University

UNKNOWN

collaborator

Nanjing First Hospital, Nanjing Medical University

OTHER

collaborator

Xiangya Hospital of Central South University

OTHER

collaborator

The First Affiliated Hospital of Bengbu Medical University

OTHER

lead

Nanjing Medical University

OTHER

NCT04918108 - Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Multicenter Cohort Study) III | Biotech Hunter | Biotech Hunter